ANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization

Area of Science:

• Biochemistry
• Molecular Biology
• Hepatology

Background:

• Angiopoietin-like protein 3 (ANGPTL3) is crucial for lipoprotein homeostasis.
• Monoclonal antibodies targeting ANGPTL3 effectively lower lipoproteins in certain genetic conditions.
• Previous attempts to reduce hepatic ANGPTL3 synthesis with antisense oligonucleotides led to adverse liver effects.

Purpose of the Study:

• To investigate the intracellular effects of ANGPTL3 downregulation on hepatocyte lipid content.
• To determine if reduced ANGPTL3 synthesis could cause a primary increase in neutral lipids within hepatocytes.

Main Methods:

• Silencing RNA was used to downregulate ANGPTL3 expression in various human hepatocyte models.
• Experiments included 2D cell cultures (HepG2, Hep3B2, Huh7) and 3D spheroids (primary human hepatocytes, HepG2/LX-2).

Main Results:

• ANGPTL3 downregulation consistently increased intracellular neutral lipids across all tested models.
• A significant finding was the reduction in deiodinase type 1 protein levels, impairing beta-oxidation.
• This impairment led to increased triglyceride accumulation in hepatic lipid droplets.

Conclusions:

• Intracellular ANGPTL3 silencing via RNA interference results in elevated triglyceride content in hepatocytes.
• The mechanism involves reduced energy substrate utilization, leading to a state resembling intracellular hepatocyte hypothyroidism.
• These findings highlight potential risks associated with ANGPTL3-targeted therapies affecting intracellular synthesis.